Compare VSH & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSH | TYRA |
|---|---|---|
| Founded | 1962 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1994 | 2021 |
| Metric | VSH | TYRA |
|---|---|---|
| Price | $22.34 | $35.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $18.00 | ★ $46.78 |
| AVG Volume (30 Days) | ★ 1.6M | 931.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 69.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,069,048,000.00 | N/A |
| Revenue This Year | $12.58 | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.48 | N/A |
| 52 Week Low | $10.57 | $7.80 |
| 52 Week High | $22.00 | $40.65 |
| Indicator | VSH | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 73.50 | 46.37 |
| Support Level | $14.55 | $34.01 |
| Resistance Level | N/A | $39.90 |
| Average True Range (ATR) | 0.95 | 2.46 |
| MACD | 0.52 | -0.39 |
| Stochastic Oscillator | 95.53 | 19.28 |
Vishay Intertechnology Inc provides a broad product portfolio of discrete semiconductors and passive electronic components to original equipment manufacturers and distributors. These products are found in industrial, computing, automotive, consumer, telecommunications, power supplies, military, aerospace, and medical markets and serve customer all over the world. Its product segments consist of two general classes: semiconductors and passive components. The company's operating segment includes metal oxide semiconductor field-effect transistors, diodes, optoelectronic components, resistors, inductors, and capacitors. Revenue mainly comes from resistors, which are basic components used in all forms of electronic circuitry to adjust and regulate levels of voltage and current.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.